Cargando…

GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes

Bone marrow (BM) fibrosis was thought to be induced exclusively by mesenchymal stromal cells (MSCs). However, we and others found that neoplastic fibrocytes induce BM fibrosis in myelofibrosis (MF). Because glioma-associated oncogene-1 (GLI1), an effector of the Hedgehog pathway, plays a role in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manshouri, Taghi, Veletic, Ivo, Li, Ping, Yin, C. Cameron, Post, Sean M., Verstovsek, Srdan, Estrov, Zeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122946/ https://www.ncbi.nlm.nih.gov/pubmed/35595725 http://dx.doi.org/10.1038/s41419-022-04932-4

Ejemplares similares

Altered T-cell subset repertoire affects treatment outcome of patients with myelofibrosis
por: Veletic, Ivo, et al.
Publicado: (2020)

Primary myelofibrosis marrow-derived CD14(+)/CD34(-) monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes
por: Manshouri, Taghi, et al.
Publicado: (2019)

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2016)

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
por: Rozovski, Uri, et al.
Publicado: (2021)

P1025: A PILOT STUDY OF THE ANTI-SLAMF7 MONOCLONAL ANTIBODY, ELOTUZUMAB, IN PATIENTS WITH MYELOFIBROSIS.
por: Bose, Prithviraj, et al.
Publicado: (2023)

Fibrocytes in primary myelofibrosis
por: Shimoda, Kazuya, et al.
Publicado: (2021)

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
por: Verstovsek, Srdan, et al.
Publicado: (2023)

Targeting cistrome and dysregulated transcriptome of post-MPN sAML
por: Verstovsek, Srdan, et al.
Publicado: (2017)

How I manage anemia related to myelofibrosis and its treatment regimens
por: Verstovsek, Srdan
Publicado: (2023)

A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis
por: Jain, Preetesh, et al.
Publicado: (2017)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity
por: Cutolo, Maurizio, et al.
Publicado: (2021)

The role of fibrocytes in fibrotic diseases of the lungs and heart
por: Keeley, Ellen C, et al.
Publicado: (2011)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Correction: Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity
por: Cutolo, Maurizio, et al.
Publicado: (2023)

Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
por: Bryan, Jeffrey C., et al.
Publicado: (2016)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments
por: Chifotides, Helen T., et al.
Publicado: (2023)

Aging promotes pro-fibrotic matrix production and increases fibrocyte recruitment during acute lung injury
por: Sueblinvong, Viranuj, et al.
Publicado: (2014)

Fibrocytes in the fibrotic lung: altered phenotype detected by flow cytometry
por: Reese, Charles, et al.
Publicado: (2014)

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes
por: Mughal, Tariq I, et al.
Publicado: (2014)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
por: Verstovsek, Srdan, et al.
Publicado: (2023)

P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER
por: Masarova, L., et al.
Publicado: (2022)

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
por: Sato, Seidai, et al.
Publicado: (2017)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
por: Randhawa, Jasleen, et al.
Publicado: (2012)

Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
por: Rajasekaran, Arun, et al.
Publicado: (2015)

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Defining disease modification in myelofibrosis in the era of targeted therapy
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA
por: Palacio, Melisa, et al.
Publicado: (2023)

Sustained‐release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
por: Verstovsek, Srdan, et al.
Publicado: (2018)

Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV): results of a phase 2 study after a 7-year median follow-up
por: Masarova, Lucia, et al.
Publicado: (2017)

Biological drivers of clinical phenotype in myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2022)

Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial
por: Jain, Preetesh, et al.
Publicado: (2017)

P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
por: Palandri, Francesca, et al.
Publicado: (2023)

Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
por: Gerds, Aaron T., et al.
Publicado: (2022)

Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
por: Kvasnicka, Hans Michael, et al.
Publicado: (2018)

Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
por: Cattaneo, Daniele, et al.
Publicado: (2022)

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
por: Verstovsek, Srdan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vj8f0ovep5i8oequm1ha7qprfg